Aardvark Therapeutics Gets $29M In Series B

San Diego-based Aardvark Therapeutics, a biopharmaceuticals company focused on metabolic diseases, said this morning that it has raised $29M in its Series B funding round. The funding was led by Sorrento Therapeutics, and also included Vickers Venture Partners, Premier Partners, BNH Investment, and Korea Omega, along with The Foundation for Prader-Willi Research. The company said the funding will go towards three Phase 2 clinical trails of its lead compound, and to advance several potential additional formulations.